Trials / Unknown
UnknownNCT03948828
Clinical Study of NK Cells in the Treatment of Severe Endometriosis
Clinical Study on the Treatment of Endometriosis by Combining With the Pathogenesis of Endometriosis and the Application Characteristics of NK Cells
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Shenzhen People's Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Dysfunction of natural koller cells (NK cells) is an important factor in the development of endometriosis. NK cell therapy was applied to treat severe endometriosis, which is an exploration of the pathogenesis of this refractory disease.
Detailed description
Endometriosis (EMs) is one of the common and frequently occurring diseases in women of childbearing age, which seriously affects the health and quality of life of the vast majority of women. The pathogenesis of endometriosis is unknown until now, and the recurrence rate of existing treatment methods is high. It is more and more necessary to introduce new therapeutic methods and strategies in view of the mechanism associated with the reduction of natural killer cell (NK) cytotoxicity. In this study, routine therapy combined with NK cell therapy was used in the treatment of severe endometriosis. The clinical data were collected to confirm the efficacy and safety of NK cell therapy. It is expected to provide a new way of thinking and method for the clinical treatment of EMs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous NK cell therapy | After conventional treatment, the patients were treated with autologous NK cells. |
| DRUG | GnRHa combained with reverse addition therapy | Postoperative patients were treated with GnRHa combined with reverse addition treatment. |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2022-05-31
- Completion
- 2022-12-31
- First posted
- 2019-05-14
- Last updated
- 2019-05-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03948828. Inclusion in this directory is not an endorsement.